We recently published 12 Stocks on Jim Cramer’s Radar. Eli Lilly and Company (NYSE:LLY) is one of the stocks on Jim Cramer’s radar.
Healthcare giant Eli Lilly and Company (NYSE:LLY) is one of Cramer’s top stocks in the sector. Throughout 2025, the CNBC TV host praised the company, not only for its weight loss drug but also for its manufacturing capacity and drug pipeline. Eli Lilly and Company (NYSE:LLY)’s shares are up by 20% over the past year and are down by 2% year-to-date. Goldman Sachs was out with an optimistic note for the firm in early February as it raised the share price target to $1,260 from $1,145 and kept a Buy rating on the shares. Like Goldman, JPMorgan also raised the share price target in February. It bumped the target up to $1,300 from $1,150 and kept an Overweight rating on the stock. JPMorgan’s enthusiasm followed Eli Lilly and Company (NYSE:LLY)’s fourth quarter earnings. The bank commented that the pharmaceutical company has growth potential due to its presence in the phase diabetes and obesity markets. Cramer didn’t hold back either when mentioning Eli Lilly and Company (NYSE:LLY):
Pixabay/Public domain
“I think you have recognize that Eli Lilly is maybe the great drug company on Earth.”
While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
